Breaking News Instant updates and real-time market news.

CPST

Capstone Turbine

$0.93

0.0602 (6.91%)

, CEVA

Ceva

$27.85

-0.63 (-2.21%)

04:55
03/19/19
03/19
04:55
03/19/19
04:55

Roth Capital to hold a conference

31st Annual ROTH Conference to be held in Dana Point, CA on March 17-19.

CPST

Capstone Turbine

$0.93

0.0602 (6.91%)

CEVA

Ceva

$27.85

-0.63 (-2.21%)

ORA

Ormat Technologies

$55.25

-0.12 (-0.22%)

ATEA

Astea

$0.00

(0.00%)

AKTS

Akoustis

$6.47

-0.02 (-0.31%)

ALRM

Alarm.com

$61.72

0.74 (1.21%)

VERI

Veritone

$6.49

0.23 (3.67%)

WAAS

AquaVenture

$19.78

-0.6 (-2.94%)

SRAX

Social Reality

$2.65

-0.06 (-2.21%)

MOBL

MobileIron

$5.03

0.03 (0.60%)

RUN

Sunrun

$14.85

0.09 (0.61%)

QTNA

Quantenna Communications

$21.07

-0.21 (-0.99%)

CWCO

Consolidated Water

$13.49

0.09 (0.67%)

EVER

EverQuote

$7.50

0.18 (2.46%)

PXLW

Pixelworks

$4.12

0.33 (8.71%)

BBSI

Barrett Business

$79.51

0.04 (0.05%)

FIVN

Five9

$54.86

0.43 (0.79%)

TMDI

Titan Medical

$3.29

(0.00%)

MNLO

Menlo Therapeutics

$7.98

0.15 (1.92%)

CRWS

Crown Crafts

$5.22

-0.025 (-0.48%)

ASUR

Asure Software

$6.22

-0.03 (-0.48%)

BOXL

Boxlight

$2.85

0.09 (3.26%)

CTEK

CynergisTek

$4.55

0.11 (2.48%)

EIDX

Eidos Therapeutics

$20.22

0.54 (2.74%)

IOTS

Adesto Technologies

$6.33

-0.1 (-1.56%)

SUMR

Summer Infant

$0.75

0.0024 (0.32%)

  • 19

    Mar

  • 19

    Mar

  • 19

    Mar

  • 20

    Mar

  • 20

    Mar

  • 25

    Mar

  • 25

    Mar

  • 25

    Mar

  • 26

    Mar

  • 28

    Mar

  • 28

    Mar

  • 28

    Mar

  • 21

    May

  • 28

    May

  • 11

    Jun

CPST Capstone Turbine
$0.93

0.0602 (6.91%)

12/31/18
HCWC
12/31/18
NO CHANGE
Target $2
HCWC
Buy
Capstone Turbine shares could rebound on 2019 catalysts, says H.C. Wainwright
H.C. Wainwright analyst Amit Dayal believes the 50% pullback in shares of Capstone Turbine since mid-July overlooks the company's revenue and margin drivers. There are "several catalysts in the story that support a healthy outlook for the company," Dayal tells investors in a research note. These include the recently launched Distributor Support System with $1.1M in funding, demand for lower cost remanufactured systems, expansion in Russia, Middle East, Africa and South America, Dayal writes. He maintains a Buy rating on Capstone Turbine with a $2.00 price target.
08/01/18
MAXM
08/01/18
INITIATION
Target $2.5
MAXM
Buy
Capstone Turbine initiated with a Buy at Maxim
Maxim analyst James Jang initiated Capstone Turbine with a Buy rating and a price target of $2.50. The analyst notes that the company's market divsersification should support its revenue expansion trend as it builds sales momentum. Jang further states that the shale oil industry is a key driver for Capstone's growth as its microturbines allow for reduced operating costs for its customers.
08/01/18
08/01/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Capstone Turbine (CPST) initiated with a Buy at Maxim. 2. Lilis Energy (LLEX) initiated with a Buy at Stifel. 3. SS&C (SSNC) assumed with an Overweight at JPMorgan. 4. Magnolia Oil & Gas (MGY) initiated with an Outperform at Imperial Capital. 5. Fate Therapeutics (FATE) initiated with a Buy at Citi. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/08/19
ROTH
02/08/19
DOWNGRADE
Target $0.9
ROTH
Neutral
Capstone Turbine downgraded to Neutral from Buy at Roth Capital
Roth Capital analyst Craig Irwin downgraded Capstone Turbine to Neutral from Buy after the company's Q3 revenue missed expectations, noting that its microturbine gross margins were negative again. The analyst, who now thinks material progress on microturbine gross margins "is looking increasingly unlikely," expects product margins excluding parts and spares to be a "source of continued disappointment," he tells investors in a post-earnings research note. Irwin lowered his price target on Capstone shares to 90c from $1.25.
CEVA Ceva
$27.85

-0.63 (-2.21%)

08/08/18
ROTH
08/08/18
NO CHANGE
Target $35
ROTH
Buy
Ceva price target lowered to $35 from $44 at Roth Capital
Roth Capital analyst Suji Desilva lowered his price target for Ceva to $35 from $44 as smartphone baseband results were mixed with a measured wireless infrastructure ramp now expected in 2H18. The analyst reiterates a Buy rating on the shares.
02/14/19
ADAM
02/14/19
NO CHANGE
Target $35
ADAM
Buy
Ceva price target lowered to $35 from $41 at Canaccord
Canaccord analyst T. Michael Walkley lowered his price target on Ceva to $35 from $41 following inline Q4 results. The analyst believes the company remains on track for strong growth of non-baseband royalty revenue, citing its product portfolio and broadening licensing portfolio. The analyst lowered his estimates and price target due to weaker royalty expectations through 2020. Walkley maintained his Buy rating on Ceva shares.
02/14/19
NORL
02/14/19
DOWNGRADE
NORL
Market Perform
Ceva downgraded to Market Perform from Outperform at Northland
Northland analyst Auguste Richard downgraded Ceva to Market Perform from Outperform.
11/28/18
11/28/18
NO CHANGE

Ceva and Tempow partner for True Wireless Stereo Bluetooth earbuds
CEVA and Tempow unveiled a collaboration to bring True Wireless Stereo to the Bluetooth earbud mass market. The resulting joint IP solution delivers synchronized left/right audio over standard Bluetooth dual mode connected links with short latency and without the power consumption penalty associated with many of today's TWS implementations.
ORA Ormat Technologies
$55.25

-0.12 (-0.22%)

03/06/19
JPMS
03/06/19
DOWNGRADE
Target $60
JPMS
Neutral
Ormat Technologies downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Paul Coster downgraded Ormat Technologies to Neutral with an unchanged price target of $60. The analyst sees a lack of catalysts for share appreciation in 2019.
09/17/18
OPCO
09/17/18
NO CHANGE
OPCO
Perform
Oppenheimer remains on sidelines on Ormat after meeting with VP of IR
Oppenheimer analyst Noah Kaye tells investors in a research note that he remains on the sidelines on Ormat Technologies after meeting with VP of Investor Relations Smadar Lavi for an update on key topics, telling investors in a research note that resolution of the Puna insurance claims could eliminate an overhang and possibly support multiple expansion.
08/09/18
08/09/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Ormat Technologies (ORA) upgraded to Overweight from Neutral at JPMorgan by analyst Paul Coster. The company reported mixed Q2 results and guidance owing to disruption at the Puna plant in Hawaii, but Coster believes that when excluding Puna, Ormat's execution "remains solid" and the company's long-term growth prospects "remain undimmed." 2. Wright Medical (WMGI) upgraded to Buy from Neutral at BofA/Merrill by analyst Travis Steed, who cited increased confidence in 2H 2018 and 2019 double digit growth and upside to Street estimates. Steed said growth in the core lower extremities business returned to market rates for the first time since Q1 2016 and believes it can accelerate further from new products and productivity ramps. 3. WildHorse Resource (WRD) upgraded to Buy from Hold at SunTrust by analyst Welles Fitzpatrick, who noted that the 13% decline in the stock price "makes little sense" from differentials or CapEx point of view, adding that the move in pricing does not warrant the large decline. Fitzpatrick views WildHorse Resource as a "simple, single-basin story, with distinct, quantifiable advantages such as premium oil pricing given its gulf coast access, ability to realized material savings with an in-field sand mine, and optionality to expand its midstream system." 4. ITG (ITG) upgraded to Overweight from Neutral at JPMorgan by analyst Kenneth Worthington, saying that the company's fundamentals are improving as it gains "traction on a number of fronts" that have and will continue to drive higher earnings power over time, particularly outside the U.S. 5. Comstock Resources (CRK) upgraded to Buy from Neutral at Ladenburg by analyst Michael Schmitz, who said the recent pullback in shares provides an attractive entry point. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/06/19
03/06/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. TripAdvisor (TRIP) downgraded to Underperform from Market Perform at Cowen with analyst Kevin Kopelman citing a weak start to 2019, expectations for weaker usage, and worries about younger age demos using Google (GOOG). 2. Teva (TEVA) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst David Risinger citing his belief that the stock's premium valuation largely prices in expectations for upside in the coming quarters due to cost cutting and conservative Copaxone guidance. 3. VMware (VMW) downgraded to Sell from Neutral at Goldman Sachs, while Pivotal Software (PVTL) was downgraded to Neutral from Buy. 4. Ormat Technologies (ORA) downgraded to Neutral from Overweight at JPMorgan with the firm's analyst citing a lack of catalysts for share appreciation in 2019. 5. CSX (CSX) downgraded to Hold from Buy at Stifel with analyst Michael Baudendistel saying he no longer sees a solid reason why shares should outperform the market in the next twelve months. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ATEA Astea
$0.00

(0.00%)

AKTS Akoustis
$6.47

-0.02 (-0.31%)

11/30/18
11/30/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Casa Systems (CASA) initiated with a Buy at Needham. 2. Charles Schwab (SCHW) and E-Trade (ETFC) were initiated with a Buy at Goldman Sachs. 3. Forty Seven (FTSV) initiated with a Buy at H.C. Wainwright. 4. Akoustis (AKTS) initiated with a Buy at Lake Street. 5. Everi Holdings (EVRI) initiated with a Strong Buy at Raymond James. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/18/18
CHLM
12/18/18
INITIATION
Target $8
CHLM
Buy
Akoustis initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Anthony Stoss started Akoustis (AKTS) with a Buy rating and $8 price target. The analyst notes that the company sits in a "unique position" with BAW filters designed with a proprietary single crystal structure. Its filters offer superior performance at higher frequencies than the two dominant players - Broadcom (AVGO) and Qorvo (QRVO) - as they can handle higher power, have better acoustic performance, transfer heat out much faster, and are 23-times smaller. Stoss believes these characteristics will allow Akoustis to penetrate three enormous markets in a meaningful way.
02/05/19
NORL
02/05/19
DOWNGRADE
NORL
Market Perform
Akoustis downgraded to Market Perform from Outperform at Northland
11/30/18
LSCM
11/30/18
INITIATION
Target $10
LSCM
Buy
Akoustis initiated with a Buy at Lake Street
Lake Street analyst Jaeson Schmidt started Akoustis Technologies with a Buy rating and $10 price target. The company's "differentiated" products can help it gain share in the $5.4B bulk acoustic wave radio frequency filter market, Schmidt tells investors in a research note. He says Akoustis' expanding engagement pipeline will start to flow to profits in a "meaningful way" in the coming years.
ALRM Alarm.com
$61.72

0.74 (1.21%)

03/04/19
IMPC
03/04/19
DOWNGRADE
Target $61
IMPC
In-Line
Alarm.com downgraded to In-Line from Outperform at Imperial Capital
Imperial Capital analyst Jeff Kessler downgraded Alarm.com to In-Line from Outperform while raising his price target for the shares to $61 from $58. The stock has appreciated 74% to $65 on February 27 from its interim low of $37.29 on June 2, 2018, but has since settled back up to the recent price of $59.31, Kessler tells investors in a research note. The analyst recommends waiting for a lower entry point into the name. He also expects comparisons to be tough in 2019.
03/01/19
JEFF
03/01/19
NO CHANGE
Target $71
JEFF
Buy
Alarm.com price target raised to $71 from $60 at Jefferies
Jefferies analyst John DiFucci raised his price target for Alarm.com to $71 saying the company in Q4 exceeded estimates on all metrics. However, its 2019 subscription guidance was below Street estimates and implies a slowdown, DiFucci tells investors in a research note. He notes the Alarm.com tends to guide "prudently" and keeps a Buy rating on the shares.
11/13/18
IMPC
11/13/18
UPGRADE
Target $58
IMPC
Outperform
Alarm.com upgraded to Outperform from In-Line at Imperial Capital
Imperial Capital analyst Jeff Kessler upgraded Alarm.com to Outperform while lowering his price target for the shares to $58 from $60. The shares are attractive after declining 19% from recent highs, Kessler tells investors in a research note. The company posted a "strong" Q3 performance, and its guidance for Q4 and 2018 is above consensus, adds the analyst. He also believes the market may be underestimating Alarm.com's non-residential opportunity. Kessler sees the company as an emerging leader in software-as-a-service platforms for small/medium businesses.
01/08/19
FANA
01/08/19
NO CHANGE
Target $65
FANA
Strong Buy
Alarm.com to maintain momentum in 2019, says First Analysis
First Analysis analyst Howard Smith kept his Strong Buy rating and $65 price target on Alarm.com. The analyst sees the company as "exceptionally well positioned in the wireless interactive security market" in 2019 and expects its momentum to "reward investors with above-market returns".
VERI Veritone
$6.49

0.23 (3.67%)

12/11/18
ROTH
12/11/18
NO CHANGE
Target $15
ROTH
Buy
Likeliness of Apis acquiring Veritone low for now, says Roth Capital
Roth Capital analyst Darren Aftahi notes that Apis Capital's PE group submitted an offer to take Veritone private in an all-cash deal for about $10.26/share. It appears Veritone has been hesitant to negotiate with Apis, which suggests the likeliness of a transaction is low, he contends. The analyst continues to look for expansion of Veritone's platform in new product use cases and cash burn mitigation as catalysts to drive shares higher. Aftahi reiterates a Buy rating and $15 price target on the stock.
12/21/18
DADA
12/21/18
NO CHANGE
Target $12
DADA
Buy
Veritone likely to trade a bit lower on Apis pulling bid, says DA Davidson
DA Davidson analyst Thomas Diffely believes Veritone shares will likely trade a bit lower on news that Apis Capital Management has withdrawn its offer to acquire the company for $10.26 per share, but he also believes the recent decline in stock price and significant discount versus the offer price show there was already "plenty of deal skepticism." He continues to value Veritone as an independent company and keeps a Buy rating and $12 price target on the stock based on future earnings potential, Diffely said.
11/13/18
11/13/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Veritone (VERI) upgraded to Neutral from Sell at B. Riley FBR with analyst Sameet Sinha citing the company's better than expected Q3 results and increased business visibility for the upgrade to Neutral. 2. Nvidia (NVDA) upgraded to Positive from Neutral at Susquehanna while Xilinx (XLNX) was upgraded to Positive from Neutral. 3. Koppers Holdings (KOP) upgraded to Buy from Neutral at Monness Crespi. 4. Southwestern Energy (SWN) upgraded to Neutral from Underperform at BofA/Merrill with analyst Doug Leggate saying U.S. natural gas prices have lifted by 50c in the past 3 weeks and $1 since September as cold weather forecasts have been updated. 5. SailPoint (SAIL) upgraded to Buy from Neutral at Goldman Sachs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/14/18
CHLM
11/14/18
NO CHANGE
Target $14
CHLM
Buy
Veritone price target lowered to $14 from $22 at Craig-Hallum
Craig-Hallum analyst Chad Bennett lowered his price target for Veritone to $14 from $22, while reiterating a Buy rating on the shares. The analyst notes that the stock is currently near all-time lows, but believes further execution on revenue growth and EBITDA improvement should provide meaningful upside to investors from current levels.
WAAS AquaVenture
$19.78

-0.6 (-2.94%)

10/02/18
10/02/18
DOWNGRADE

Outperform
AquaVenture downgraded to Outperform on Ghana delay at Raymond James
As previously reported, Raymond James downgraded AquaVenture to Outperform from Strong Buy and maintained a $22 price target. Analyst Pavel Molchanov said said the delay in the Ghana desalination plant closing is disappointing and will take up more of management's attention, and less bandwidth to devote to M&A opportunities.
12/19/18
LSCM
12/19/18
NO CHANGE
Target $34
LSCM
Buy
AquaVenture price target raised to $34 from $32 at Lake Street
Lake Street analyst Robert Brown raised his price target for AquaVenture to $34 after the company's Quench unit acquired Pure Health Solutions for $58M. The acquisition brings scale to seven U.S. markets, including one new market, Brown tells investors in a research note. His new price target reflects a higher EBITDA run-rate. The analyst keeps a Buy rating on AquaVenture.
09/18/18
JMPS
09/18/18
NO CHANGE
Target $24
JMPS
Outperform
Ruling may help expedite AquaVenture deal in Ghana, says JMP Securities
JMP Securities analyst Joseph Osha noted that Ghanaian news sources reported late last week that the entity responsible for overseeing utilities in the country issued a ruling that may help expedite a resolution to a water pricing dispute, which brings the complex process surrounding AquaVenture's plans to buy some or all of a large Ghanaian water desalination plant one step closer to completion. Osha now sees higher odds that AquaVenture will have a Ghanaian deal by the end of the year, if not by September 30, he tells investors. He maintains an Outperform rating on AquaVenture.
10/02/18
RAJA
10/02/18
DOWNGRADE
RAJA
Outperform
AquaVenture downgraded to Outperform from Strong Buy at Raymond James
SRAX Social Reality
$2.65

-0.06 (-2.21%)

MOBL MobileIron
$5.03

0.03 (0.60%)

RUN Sunrun
$14.85

0.09 (0.61%)

09/11/18
BOFA
09/11/18
UPGRADE
BOFA
Buy
Sunrun upgraded to Buy from Neutral at BofA/Merrill
09/11/18
BOFA
09/11/18
UPGRADE
Target $17
BOFA
Buy
Sunrun upgraded to Buy on valuation, reduced risks at BofA/Merrill
As previously reported, BofA/Merrill upgraded Sunrun to Buy from Neutral and raised its price target to $17 from $16. Analyst Julien Dumoulin-Smith said recent share underperformance has led to limited downside risk, combined with his increased confidence in both deployments and cost reductions, and positive SB100 legislation signed in California, will lead to acceleration in volumes.
08/13/18
BOFA
08/13/18
UPGRADE
BOFA
Neutral
Sunrun upgraded to Neutral from Underperform at BofA/Merrill
BofA//Merrill analyst Julien Dumoulin-Smith upgraded Sunrun to Neutral from Underperform and raised its price target to $16 from $15 citing valuation. The analyst said the recent pullback in shares following the Q2 report is an overreaction and notes the acceleration in deployments and the continued shift to direct sales.
08/10/18
ROTH
08/10/18
NO CHANGE
Target $18
ROTH
Buy
Sunrun price target raised to $18 from $13 at Roth Capital
Roth Capital analyst Philip Shen reiterated a Buy rating on Sunrun and raised his price target to $18 from $13 after the company delivered a "healthy" Q2 and backed its full year outlook. While the company's Q3 guidance was "a bit light," Shen tells investors in a research note that management is "quite confident" of its aggressive Q4 outlook calling for deployments up 14% q/q and 33% y/y.
QTNA Quantenna Communications
$21.07

-0.21 (-0.99%)

09/05/18
ROTH
09/05/18
NO CHANGE
Target $25
ROTH
Buy
Quantenna Communications price target raised to $25 from $20 at Roth Capital
Roth Capital analyst Suji Desilva raised his price target for Quantenna Communications to $25 from $20 as he is encouraged by the announcement that Deutsche Telekom will use its 10G 802.11ac Wave 3 product for its flagship Speedport Pro router. The analyst believes diversification outside core cable MSO validates the technological superiority of the company's offering. He reiterates a Buy rating on the shares.
01/17/19
LEHM
01/17/19
DOWNGRADE
Target $14
LEHM
Underweight
Quantenna downgraded to Underweight from Equal Weight at Barclays
Barclays analyst Blayne Curtis downgraded Quantenna Communications to Underweight and lowered his price target for the shares to $14 from $17.
10/18/18
STFL
10/18/18
NO CHANGE
STFL
Stifel lowers analog and IoT semiconductor estimates on broad-based slowdown
Stifel analyst Tore Svanberg said he expects Q3 to come in essentially in line with expectations for analog and IoT semiconductor companies, but sees their Q4 outlooks being impacted by a potential supply-chain correction or slower end-market growth. He now believes 2019 will now be a down year, projecting a 2%-4% contraction, and sees companies aligned with strong secular growth stories as poised to outperform their peers. Svanberg identifies Monolithic Power (MPWR), Silicon Labs (SLAB), Semtech (SMTC) and Quantenna (QTNA) as among the companies he sees being aligned with strong secular growth stories. In conjunction with the sector preview, Svanberg lowered his price targets on Monolithic Power, Silicon Labs, Alpha & Omega (AOSL), Macom (MTSI), Maxim Integrated (MXIM), MaxLinear (MXL), NXP Semiconductors (NXPI), O2Micro (OIIM), Power Integrations (POWI) and Texas Instruments (TXN).
01/10/19
STFL
01/10/19
NO CHANGE
Target $22
STFL
Buy
Quantenna competitive positioning 'as strong as ever,' says Stifel
After hosting investor meetings at CES 2019 with Quantenna's CEO and CFO, Stifel analyst Tore Svanberg said he believes the company's competitive positioning and innovation are "as strong as ever." High-end Wi-Fi/802.11ax is "even more compelling in a 5G world," while the company's dominance of the cable MSO/service provider space gives it significant financial and competitive advantages, said Svanberg, who thinks those focused on near-term concerns are "missing the big picture." He keeps a Buy rating and $22 price target on Quantenna Communications shares.
CWCO Consolidated Water
$13.49

0.09 (0.67%)

EVER EverQuote
$7.50

0.18 (2.46%)

02/26/19
OPCO
02/26/19
NO CHANGE
Target $11
OPCO
Outperform
EverQuote price target lowered to $11 from $16 at Oppenheimer
Oppenheimer analyst Jed Kelly lowered his price target for EverQuote to $11 from $16 following quarterly results, which suggest Q4 traffic headwinds were company specific. The analyst reiterates an Outperform rating on the shares as he is more encouraged toward the company's long-term outlook after it guided 2019 revenue above the Street on more balanced growth between pricing and volume, that implies Q4 marketing initiatives are re-accelerating profitable traffic.
02/26/19
ADAM
02/26/19
NO CHANGE
Target $12
ADAM
Buy
EverQuote Q4 results showed trends stabilizing, says Canaccord
Canaccord analyst Michael Graham said the Q4 results for EverQuote showed encouraging signs of stabilization. He noted revenue growth was driven by a balance of volume and revenue per quote request. He is now looking ahead to positive milestones, including the launch of renters and commercial verticals and the roll-out of EverDrive to over 20 more states. Graham reiterated his Buy rating and lowered his price target to $12 from $14 on EverQuote shares.
02/26/19
02/26/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Exact Sciences (EXAS) upgraded to Buy from Neutral at Goldman Sachs by analyst Patrick Donnelly, who said the current momentum of the Cologuard commercial ramp provides "strong basis" for the company's premium valuation while the combination of positive Cologuard catalysts and new product roll-outs provide upside to current levels, even after the stock's 75% rally since the beginning of 2018. Exact Sciences is a "must-own growth stock" given the "clean runway forward that is largely in its control with potential for discovery value in the pipeline outside of Cologuard," the analyst said. 2. Siemens (SIEGY) upgraded to Overweight from Neutral at JPMorgan by analyst Andreas Willi, who sees a relative valuation opportunity after the stock's 27% underperformance over the past two years. He believes investor sentiment can improve "after a period where the story has drifted." 3. Kadmon (KDMN) upgraded to Buy from Neutral at Citi by analyst Robyn Karnauskas, who assigned a 50% probability to KD-025 in chronic graft versus host disease with an unadjusted ~$900M market opportunity. However, upside to the stock will depend on quality of the data likely, Karnauskas said. 4. EverQuote (EVER) upgraded to Buy following Q4 beat at BofA/Merrill by analyst Mat Schindler, who said user growth has re-accelerated, supporting evidence of a turnaround, and thinks estimates are conservative and views the risk/reward as attractive. 5. Ally Financial (ALLY) upgraded to Buy from Hold at Sandler O'Neill by analyst Christopher Donat, who said he believes Ally's near-prime auto finance book is "meaningfully less risky" than Santander Consumer's (SC) book or the unsecured credit cards of Discover (DFS) and Capital One (COF), yet all four stocks trade at similar multiples. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/26/19
BOFA
02/26/19
UPGRADE
Target $10.5
BOFA
Buy
EverQuote upgraded to Buy following Q4 beat at BofA/Merrill
As previously reported, BofA/Merrill upgraded EverQuote to Buy from Neutral with a new $10.50 price target following the Q4 beat. Analyst Nat Schindler said user growth has re-accelerated, supporting evidence of a turnaround, and thinks estimates are conservative and views the risk/reward as attractive.
PXLW Pixelworks
$4.12

0.33 (8.71%)

10/05/18
ROTH
10/05/18
NO CHANGE
ROTH
Buy
Pixelworks a differentiated investment opportunity, says Roth Capital
Roth Capital analyst Suji Desilva maintained a Buy rating on Pixelworks, telling investors in a research note that the company represents a differentiated investment opportunity in video display processing capabilities. Desilva says he is "encouraged" by HMD Global's Nokia 7.1 mainstream smartphone, utilizes the company's Iris Gen 4 mobile processor.
08/31/18
ROTH
08/31/18
NO CHANGE
Target $7
ROTH
Buy
Roth Capital encouraged by good reviews for Pixelworks-powered Axon 9
Roth Capital analyst Suji Desilva said he was encouraged by positive reviews for ZTE's (ZTCOY) Axon 9 smartphone, which uses Pixelworks' (PXLW) Iris mobile processor. Of note, reviews have emphasized the high aspect ratio OLED display and viewing quality, affirming his constructive thesis on the value of Pixelworks' core video technology, Desilva tells investors. He raised his price target on Pixelworks shares to $7 from $6 and maintains a Buy rating on the stock.
05/30/18
LSCM
05/30/18
NO CHANGE
Target $6.5
LSCM
Buy
Pixelworks positioned for 'meaningful' sales growth, says Lake Street
Lake Street analyst Jaeson Schmidt left a visit to Pixelworks headquarters continuing to believe the company can see "meaningful" sales growth longer-term driven by its mobile and video delivery businesses. He believes Pixelworks' mobile business, while still small, has "strong" pipeline and customer engagements, which will likely lead to additional win announcements later this year. The analyst reiterates a Buy rating on the shares with a $6.50 price target.
09/05/18
NORL
09/05/18
INITIATION
Target $8.5
NORL
Outperform
Pixelworks initiated with an Outperform at Northland
Northland initiated Pixelworks with an Outperform and $8.50 price target.
BBSI Barrett Business
$79.51

0.04 (0.05%)

05/03/18
ROTH
05/03/18
NO CHANGE
Target $100
ROTH
Buy
Barrett Business price target lowered to $100 from $105 at Roth Capital
Roth Capital analyst Jeff Martin lowered his price target for Barrett Business to $100 from $105 following quarterly results. The analyst reiterates a Buy rating on the shares.
02/28/19
ROTH
02/28/19
NO CHANGE
Target $109
ROTH
Buy
Barrett Business price target raised to $109 from $100 at Roth Capital
Roth Capital analyst Jeff Martin raised his price target for Barrett Business to $109 from $100 after Q4 EPS beat his estimate by a wide margin, despite revenue below his estimate. The analyst reiterates a Buy rating on the shares given the company's ability to accelerate the growth rate of the PEO model to a double-digit organic growth rate.
10/09/18
SIDC
10/09/18
INITIATION
Target $95
SIDC
Buy
Barrett Business initiated with a Buy at Sidoti
Target $95.
FIVN Five9
$54.86

0.43 (0.79%)

02/20/19
ADAM
02/20/19
NO CHANGE
Target $60
ADAM
Buy
Five9 price target raised to $60 from $45 at Canaccord
Canaccord analyst David Hynes raised his price target on Five9 to $60 from $45 following Q4 results he called "solid." The analyst noted its valuation is not cheap and said he would be a better buyer on any dips. He sees very few competitive threats, continued innovation keeping revenue growth intact, and longer term he sees the company as a strategic target for an acquirer. Hynes reiterated his Buy rating on Five9 shares.
02/20/19
CHLM
02/20/19
NO CHANGE
Target $64
CHLM
Buy
Five9 price target raised to $64 from $46 at Craig-Hallum
Craig-Hallum analyst Jeff Van Rhee raised his price target for Five9 to $46 from $64 following quarterly results. The analyst believes the runway remains very long for the company, with Five9 continuing to execute like a well-oiled machine. He reiterates a Buy rating on the shares.
02/20/19
NEED
02/20/19
NO CHANGE
Target $65
NEED
Buy
Five9 price target raised to $65 from $50 at Needham
Needham analyst Scott Berg raised his price target on Five9 to $65 and kept his Buy rating after its "strong" Q4 results with over 30% revenue growth. The analyst believes that Five9 expectations for FY19 remain conservative and beatable as it continues to invest in "R&D to support its AI initiatives and S&M to scale its go-to-market". Berg further contends that the company is a "cloud leader in the contact center market, which remains at the early stages of the cloud transition."
02/20/19
ROTH
02/20/19
NO CHANGE
Target $62
ROTH
Buy
Five9 price target raised to $62 from $55 at Roth Capital
Roth Capital analyst Richard Baldry raised his price target for Five9 to $62 from $55 saying that while the shares are up 24% year-to-date, Q4 results still support a bullish outlook. The analyst believes Five9's increased valuation multiples can be sustained given its strong execution. He reiterates a Buy rating on the stock.
TMDI Titan Medical
$3.29

(0.00%)

09/17/18
NORL
09/17/18
INITIATION
Target $6
NORL
Outperform
Titan Medical initiated with an Outperform at Northland
Northland analyst Suraj Kalia initiated Titan Medical with an Outperform and $6 price target.saying its an emerging player in the single-port robotic surgery space, and the only other company besides Intuitive Surgical to offer a platform for targeted segments, and an attractive micro-cap play.
MNLO Menlo Therapeutics
$7.98

0.15 (1.92%)

09/06/18
CANT
09/06/18
INITIATION
Target $25
CANT
Overweight
Cantor sees positive data driving Menlo shares higher, starts at Overweight
Cantor Fitzgerald analyst Louise Chen initiated coverage of Menlo Therapeutics with an Overweight rating and $25 price target. The analyst expects pipeline success to drive consensus earnings estimates and the stock higher. Chen believes a "positive, steady stream of pivotal data readouts" for Nularis, Tussix and Psorixa will begin in Q4 of this year.
09/06/18
CANT
09/06/18
INITIATION
Target $25
CANT
Overweight
Menlo Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen initiated Menlo Therapeutics with an Overweight and $25 price target.
07/24/18
ROTH
07/24/18
INITIATION
Target $29
ROTH
Buy
Menlo Therapeutics initiated with a Buy at Roth Capital
Roth Capital analyst Yasmeen Rahimi started Menlo Therapeutics with a Buy rating and $29 price target. The analyst cited the company's Phase 3 asset serlopitant for prurigo nodularis, with significant upside potential from Phase 2 programs in psoriasis-related pruritus and refractory chronic cough.
10/09/18
JEFF
10/09/18
NO CHANGE
Target $7
JEFF
Hold
Menlo Therapeutics price target lowered to $7 from $9 at Jefferies
Jefferies analyst David Steinberg lowered his price target for Menlo Therapeutics to $7 after the company said it will halt serlopitant development in chronic cough with the Phase 2 study failing to meet its endpoints. This marks the second clinical failure this year, but the rest of the program continues on post the prior Phase 2 success in prurigo nodularis and chronic pruritus, Steinberg tells investors in a research note. The analyst keeps a Hold rating on Menlo Therapeutics.
CRWS Crown Crafts
$5.22

-0.025 (-0.48%)

11/29/18
DADA
11/29/18
INITIATION
Target $6.5
DADA
Neutral
Crown Crafts initiated with a Neutral at DA Davidson
DA Davidson analyst Linda Bolton Weiser initiated Crown Crafts with a Neutral rating and a price target of $6.50. The analyst says the company is one of the leading marketers of infant, toddler, and juvenile products in the U.S." and offers a "relatively stable operating margin" and sustained dividend. However, she also sees some longer term demographic headwinds for Crown Crafts, with live U.S. births flat or down in all but one of the last 10 years. Weiser further points to reduced popularity of the company's 5-9 piece toddler bedding sets after the warning from the American Academy of Pediatrics about the risks of SIDS from crib bumpers as well as the price deflation from the devaluation of Chinese Yuan.
ASUR Asure Software
$6.22

-0.03 (-0.48%)

01/08/19
ROTH
01/08/19
NO CHANGE
Target $15
ROTH
Buy
Asure Software price target lowered to $15 from $23 at Roth Capital
Roth Capital analyst Richard Baldry lowered his price target for Asure Software to $15 from $23 given market weakness and dampened near-term investor sentiment. The analyst notes that the company announced the acquisition of Payroll Maxx, with the deal to be funded by an $8M term loan from its existing lender group and expected to add $4M to 2019 revenues. He reiterates a Buy rating on the shares.
11/13/18
DOTC
11/13/18
DOWNGRADE
DOTC
Neutral
Asure Software downgraded to Neutral from Buy at Dougherty
03/05/19
GSCO
03/05/19
DOWNGRADE
GSCO
Sell
Goldman Sachs cuts GAP Airports, Asur to Sell on lower growth forecast
Goldman Sachs analyst Bruno Amorim downgraded airports Asur (ASUR) and GAP (PCA) to Sell from Neutral and Buy respectively as part of his broader research note on the Mexico Transportation sector. The analyst says the Q4 results in the industry suggests that capacity constraints from airlines, "driven by market leader Aeromexico's decision to potentially shrink domestic capacity", could curb airport growth. The analyst also issues a double-notch upgrade of Volaris (VLRS) to Buy from Sell as part of his research note, forecasting the airline to enter a margin expansion phase after a "sharp correction" in its EBIT and amid "concrete signs" that its unit revenues RASM metric has bottomed.
01/09/19
BRRR
01/09/19
NO CHANGE
Target $15
BRRR
Outperform
Asure Software price target lowered to $15 from $20 at Barrington
Barrington analyst Vincent Colicchio lowered his price target for Asure Software to $15 to reflect a reduction in his 2019 revenue forecast as as well as "negative investor sentiment," which the analyst believes will take time to recover. However, he keeps an Outperform rating on Asure following the company's acquisition of Payroll Maxx. The deal increased Asure's direct national distribution of Evolution software and adds clients that are located throughout the U.S., Colicchio tells investors in a research note.
BOXL Boxlight
$2.85

0.09 (3.26%)

05/31/18
TAGS
05/31/18
NO CHANGE
Target $9
TAGS
Speculative Buy
Boxlight price target raised to $9 from $7 at Taglich
Taglich analyst John Nobile raised his price target on Boxlight shares to $9 from $7, noting that since the announcement of its acquisition of Cohuborate the stock's price/sales multiples have expanded, which he attributes to the potential impact this acquisition is likely to have on future sales in the U.K. Nobile maintains a Speculative Buy rating on Boxlight.
CTEK CynergisTek
$4.55

0.11 (2.48%)

EIDX Eidos Therapeutics
$20.22

0.54 (2.74%)

02/21/19
BMOC
02/21/19
INITIATION
BMOC
Outperform
Eidos Therapeutics initiated with an Outperform at BMO Capital
BMO Capital analyst George Farmer initiated Eidos Therapeutics with an Outperform rating and $28 price target. The analyst receommends buying shares as he sees huge potential for AG10 for the treatment of transthyretin amyloidosis, and estimates peak sales of $3B by 2031.
02/27/19
JPMS
02/27/19
UPGRADE
JPMS
Overweight
Eidos Therapeutics upgraded to Overweight from Neutral at JPMorgan
02/27/19
JPMS
02/27/19
UPGRADE
Target $39
JPMS
Overweight
JPMorgan says Eidos trial design removes multiple overhangs, ups to Overweight
JPMorgan analyst Anupam Rama upgraded Eidos Therapeutics to Overweight from Neutral, citing his view that the company's design of the ATTRibute-CM study, which incorporates feedback from the FDA, removes multiple overhangs, including the need for a head-to-head study versus tafamidis and a financing overhang. The analyst, who has increased his view of the probability of success for AG10 in the ATTR-CM opportunity, also believes AG10 is likely to generate strategic interest from commercial partners. Rama raised his price target on Eidos shares to $39 from $29.
02/27/19
ROTH
02/27/19
NO CHANGE
Target $28
ROTH
Buy
Eidos addressed stock major overhangs with smart trial design, says Roth Capital
Roth Capital analyst Yasmeen Rahimi believes that Eidos Therapeutics' ATTRibute-CM "smart trial design offers the best of both worlds" with two approvable endpoints, namely a 12-month, placebocontrolled study with primary endpoint of change from baseline in six-minute walk distance, and reduction in all-cause mortality and frequency of CV-related hospitalizations over 30 months. Overall, the analyst thinks the company has addressed the major stock overhangs with this smart design. First, by not waiting for tafamidis approval for a comparator, Eidos Therapeutics' will start its trial six months faster and shorten time to market, and second, it is now "rich in catalysts," Rahimi contends. The analyst reiterates a Buy rating and $28 price target on the shares.
IOTS Adesto Technologies
$6.33

-0.1 (-1.56%)

09/19/18
ADAM
09/19/18
NO CHANGE
Target $9
ADAM
Buy
Adesto Technologies acquisition expands addressable market, says Canaccord
Canaccord analyst T. Michael Walkley said the acquisition of Echelon by Adesto Technologies expands its addressable market and it is anticipated more than half the synergies of the deal will be realized during Q4 2018. The analyst raised his estimates and he believes the company is uniquely positioned in the industrial IoT market with its products to generate strong long-term earnings growth. Walkley reiterated his Buy rating and $9 price target on Adesto Technologies shares.
10/05/18
BNCH
10/05/18
NO CHANGE
Target $9
BNCH
Buy
Adesto weakness on memory pricing concerns a buying opportunity, says Benchmark
Benchmark analyst Gary Mobley attributes yesterday's weakness in shares of Adesto Technologies to a Digitimes article highlighting Nanya's Q3 revenue shortfall along with recent data points relating to weak DRAM and NAND flash pricing. However, he views yesterday price decline as an overreaction and reiterates his Buy rating on Adesto with a $9 price target.
07/30/18
COWN
07/30/18
INITIATION
Target $8
COWN
Outperform
Adesto Technologies initiated with an Outperform at Cowen
Cowen initiated Adesto Technologies with an Outperform and $8 price target.
11/01/18
RILY
11/01/18
NO CHANGE
Target $9.5
RILY
Buy
Adesto recent selloff brings buying opportunity, says B. Riley FBR
B. Riley FBR analyst Josh Nichols views Adesto Technologies as oversold and sees a "particularly attractive" buying opportunity ahead of the company's Q3 results in November 7. The analyst reiterates a Buy rating on the shares with a $9.50 price target.
SUMR Summer Infant
$0.75

0.0024 (0.32%)

TODAY'S FREE FLY STORIES

INCY

Incyte

$77.76

1.385 (1.81%)

12:52
06/16/19
06/16
12:52
06/16/19
12:52
Hot Stocks
Incyte announced results from Phase 2 study of Ruxolitinib cream in vitiligo »

Incyte announces 24-week…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

, INCY

Incyte

$77.76

1.385 (1.81%)

04:55
06/16/19
06/16
04:55
06/16/19
04:55
Conference/Events
European Hematology Association to hold a conference »

24th EHA Congress 2019…

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

INCY

Incyte

$77.76

1.385 (1.81%)

ARQL

ArQule

$8.17

1.88 (29.89%)

AMGN

Amgen

$176.09

-0.74 (-0.42%)

ALXN

Alexion

$117.94

0.65 (0.55%)

AGIO

Agios Pharmaceuticals

$47.97

-1.78 (-3.58%)

AZN

AstraZeneca

$39.68

-0.23 (-0.58%)

BLUE

Bluebird Bio

$117.57

-6.33 (-5.11%)

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

CELG

Celgene

$96.49

0.07 (0.07%)

NVS

Novartis

$89.52

-0.07 (-0.08%)

NSTG

NanoString

$25.96

0.45 (1.76%)

KPTI

Karyopharm

$5.71

-0.04 (-0.70%)

JAZZ

Jazz Pharmaceuticals

$130.43

0.28 (0.22%)

GSK

GlaxoSmithKline

$40.12

0.015 (0.04%)

GILD

Gilead

$66.38

-0.62 (-0.93%)

DSNKY

Daiichi Sankyo

$0.00

(0.00%)

PFE

Pfizer

$42.75

0.24 (0.56%)

PTLA

Portola Pharmaceuticals

$25.78

-0.31 (-1.19%)

QGEN

Qiagen

$39.52

-0.07 (-0.18%)

RHHBY

Roche

$0.00

(0.00%)

RIGL

Rigel Pharmaceuticals

$2.06

-0.06 (-2.83%)

SNY

Sanofi

$42.46

-0.225 (-0.53%)

SGEN

Seattle Genetics

$68.67

-0.33 (-0.48%)

STML

Stemline

$14.20

0.12 (0.85%)

VSTM

Verastem

$1.39

0.125 (9.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 18

    Jun

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 21

    Jun

  • 23

    Jun

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 27

    Jun

  • 28

    Jun

  • 28

    Jun

  • 06

    Jul

  • 25

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 26

    Aug

  • 28

    Aug

  • 29

    Aug

  • 02

    Sep

  • 03

    Sep

  • 16

    Sep

  • 04

    Nov

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

, GRUB

GrubHub

$70.15

-2.76 (-3.79%)

13:28
06/15/19
06/15
13:28
06/15/19
13:28
Periodicals
Amazon exit gives GrubHub stock boost, Barron's says »

Amazon (AMZN) is…

AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

GRUB

GrubHub

$70.15

-2.76 (-3.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 10

    Jul

ABC

AmerisourceBergen

$85.01

-1.46 (-1.69%)

, CAH

Cardinal Health

$44.16

-1.13 (-2.50%)

13:20
06/15/19
06/15
13:20
06/15/19
13:20
Periodicals
McKesson, Cardinal Health looking like bargains, Barron's says »

Investors have halved the…

ABC

AmerisourceBergen

$85.01

-1.46 (-1.69%)

CAH

Cardinal Health

$44.16

-1.13 (-2.50%)

MCK

McKesson

$133.19

-1.7 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

RTN

Raytheon

$177.38

0.195 (0.11%)

, UTX

United Technologies

$125.30

0.45 (0.36%)

13:09
06/15/19
06/15
13:09
06/15/19
13:09
Periodicals
United Technologies, Raytheon stocks looking cheap, Barron's says »

Shares of United…

RTN

Raytheon

$177.38

0.195 (0.11%)

UTX

United Technologies

$125.30

0.45 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 17

    Jun

  • 17

    Jun

GRUB

GrubHub

$70.15

-2.76 (-3.79%)

, AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

13:04
06/15/19
06/15
13:04
06/15/19
13:04
Periodicals
Food fight extending well beyond restaurant delivery, Barron's says »

Amazon (AMZN) is quitting…

GRUB

GrubHub

$70.15

-2.76 (-3.79%)

AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 10

    Jul

GOOGL

Alphabet Class A

$1,086.36

-4.65 (-0.43%)

, GOOG

Alphabet

$1,085.56

-3.52 (-0.32%)

12:59
06/15/19
06/15
12:59
06/15/19
12:59
Periodicals
Facebook, JPMorgan chiefs among Best CEOs of 2019, Barron's says »

Separated into three…

GOOGL

Alphabet Class A

$1,086.36

-4.65 (-0.43%)

GOOG

Alphabet

$1,085.56

-3.52 (-0.32%)

FB

Facebook

$181.35

3.88 (2.19%)

MCD

McDonald's

$205.33

0.85 (0.42%)

JPM

JPMorgan

$109.84

0.26 (0.24%)

BAC

Bank of America

$28.03

0.09 (0.32%)

BLK

BlackRock

$446.96

-1.29 (-0.29%)

BX

Blackstone

$44.13

0.17 (0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 19

    Jun

  • 09

    Jul

  • 10

    Jul

  • 16

    Jul

  • 17

    Jul

  • 06

    Aug

  • 27

    Oct

AVGO

Broadcom

$265.99

-15.96 (-5.66%)

, AAPL

Apple

$192.84

-1.93 (-0.99%)

07:17
06/15/19
06/15
07:17
06/15/19
07:17
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AVGO

Broadcom

$265.99

-15.96 (-5.66%)

AAPL

Apple

$192.84

-1.93 (-0.99%)

HNHPF

Hon Hai Precision

$0.00

(0.00%)

UTX

United Technologies

$125.30

0.45 (0.36%)

RTN

Raytheon

$177.38

0.195 (0.11%)

CGC

Canopy Growth

$41.15

-0.64 (-1.53%)

TLRY

Tilray

$38.96

-1.78 (-4.37%)

APHA

Aphria

$6.80

-0.15 (-2.16%)

ACB

Aurora Cannabis

$7.56

(0.00%)

CVSI

CV Sciences

$0.00

(0.00%)

CNTTF

CannTrust Holdings

$0.00

(0.00%)

CRON

Cronos Group

$15.43

-0.92 (-5.63%)

CANN

General Cannabis

$0.00

(0.00%)

IGC

India Globalization Capital

$1.28

0.4201 (48.85%)

MLCPF

MediPharm Labs

$0.00

(0.00%)

ZYNE

Zynerba

$13.03

-0.54 (-3.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 17

    Jun

  • 17

    Jun

  • 18

    Jun

  • 19

    Jun

  • 21

    Jun

  • 25

    Jun

  • 09

    Jul

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

, ABMD

Abiomed

$250.96

-4.58 (-1.79%)

04:55
06/15/19
06/15
04:55
06/15/19
04:55
Conference/Events
International League of Dermatological Societies to hold a conference »

24th World Congress of…

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

ABMD

Abiomed

$250.96

-4.58 (-1.79%)

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

CELG

Celgene

$96.49

0.07 (0.07%)

LLY

Eli Lilly

$111.74

-0.06 (-0.05%)

JNJ

Johnson & Johnson

$140.08

-0.63 (-0.45%)

NVS

Novartis

$89.52

-0.07 (-0.08%)

PFE

Pfizer

$42.75

0.24 (0.56%)

PG

Procter & Gamble

$111.20

0.28 (0.25%)

SNY

Sanofi

$42.46

-0.225 (-0.53%)

UL

Unilever; also tag UN

$62.61

-0.07 (-0.11%)

UN

Unilever; also tag UL

$61.30

-0.13 (-0.21%)

INCY

Incyte

$77.76

1.385 (1.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 17

    Jun

  • 26

    Jun

  • 27

    Jun

  • 16

    Jul

  • 25

    Jul

  • 30

    Jul

  • 28

    Aug

  • 03

    Sep

  • 16

    Sep

  • 13

    Nov

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

, GSK

GlaxoSmithKline

$40.12

0.015 (0.04%)

04:55
06/15/19
06/15
04:55
06/15/19
04:55
Conference/Events
European Congress of Rheumatology to hold a conference »

EULAR 2019 will be held…

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

GSK

GlaxoSmithKline

$40.12

0.015 (0.04%)

PFE

Pfizer

$42.75

0.24 (0.56%)

LLY

Eli Lilly

$111.74

-0.06 (-0.05%)

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

NVS

Novartis

$89.52

-0.07 (-0.08%)

RHHBY

Roche

$0.00

(0.00%)

BIIB

Biogen

$227.67

-3.57 (-1.54%)

AMGN

Amgen

$176.09

-0.74 (-0.42%)

SNY

Sanofi

$42.46

-0.225 (-0.53%)

CELG

Celgene

$96.49

0.07 (0.07%)

GILD

Gilead

$66.38

-0.62 (-0.93%)

REGN

Regeneron

$305.19

-2.235 (-0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 20

    Jun

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 25

    Jul

  • 30

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 26

    Aug

  • 28

    Aug

  • 29

    Aug

  • 02

    Sep

  • 03

    Sep

  • 16

    Sep

  • 04

    Nov

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

ABT

Abbott

$82.25

-0.03 (-0.04%)

, AMGN

Amgen

$176.09

-0.74 (-0.42%)

04:55
06/15/19
06/15
04:55
06/15/19
04:55
Conference/Events
Society for Vascular Surgery to hold annual meeting »

SVS Annual Meeting 2019…

ABT

Abbott

$82.25

-0.03 (-0.04%)

AMGN

Amgen

$176.09

-0.74 (-0.42%)

BSX

Boston Scientific

$40.41

-0.26 (-0.64%)

PFE

Pfizer

$42.75

0.24 (0.56%)

CRY

CryoLife

$29.13

-0.13 (-0.44%)

EW

Edwards Lifesciences

$184.00

-0.63 (-0.34%)

ELGX

Endologix

$7.61

0.2 (2.70%)

IAC

IAC

$228.41

-2.63 (-1.14%)

HCA

HCA Healthcare

$126.64

-0.76 (-0.60%)

LMAT

LeMaitre

$26.04

-0.44 (-1.66%)

ORGO

Organogenesis

$7.39

0.02 (0.27%)

OSIR

Osiris

$0.00

(0.00%)

PEN

Penumbra

$166.75

2.93 (1.79%)

SWAV

ShockWave Medical

$58.27

-0.99 (-1.67%)

WTKWY

Wolters Kluwer

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 26

    Jun

  • 09

    Aug

  • 26

    Aug

  • 26

    Aug

  • 28

    Aug

  • 16

    Sep

  • 25

    Sep

  • 13

    Nov

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

, INCY

Incyte

$77.76

1.385 (1.81%)

04:55
06/15/19
06/15
04:55
06/15/19
04:55
Conference/Events
European Hematology Association to hold a conference »

24th EHA Congress 2019…

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

INCY

Incyte

$77.76

1.385 (1.81%)

ARQL

ArQule

$8.17

1.88 (29.89%)

AMGN

Amgen

$176.09

-0.74 (-0.42%)

ALXN

Alexion

$117.94

0.65 (0.55%)

AGIO

Agios Pharmaceuticals

$47.97

-1.78 (-3.58%)

AZN

AstraZeneca

$39.68

-0.23 (-0.58%)

BLUE

Bluebird Bio

$117.57

-6.33 (-5.11%)

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

CELG

Celgene

$96.49

0.07 (0.07%)

NVS

Novartis

$89.52

-0.07 (-0.08%)

NSTG

NanoString

$25.96

0.45 (1.76%)

KPTI

Karyopharm

$5.71

-0.04 (-0.70%)

JAZZ

Jazz Pharmaceuticals

$130.43

0.28 (0.22%)

GSK

GlaxoSmithKline

$40.12

0.015 (0.04%)

GILD

Gilead

$66.38

-0.62 (-0.93%)

DSNKY

Daiichi Sankyo

$0.00

(0.00%)

PFE

Pfizer

$42.75

0.24 (0.56%)

PTLA

Portola Pharmaceuticals

$25.78

-0.31 (-1.19%)

QGEN

Qiagen

$39.52

-0.07 (-0.18%)

RHHBY

Roche

$0.00

(0.00%)

RIGL

Rigel Pharmaceuticals

$2.06

-0.06 (-2.83%)

SNY

Sanofi

$42.46

-0.225 (-0.53%)

SGEN

Seattle Genetics

$68.67

-0.33 (-0.48%)

STML

Stemline

$14.20

0.12 (0.85%)

VSTM

Verastem

$1.39

0.125 (9.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jun

  • 17

    Jun

  • 18

    Jun

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 21

    Jun

  • 23

    Jun

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 27

    Jun

  • 28

    Jun

  • 28

    Jun

  • 06

    Jul

  • 25

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 26

    Aug

  • 28

    Aug

  • 29

    Aug

  • 02

    Sep

  • 03

    Sep

  • 16

    Sep

  • 04

    Nov

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

CNC

Centene

$53.52

-0.26 (-0.48%)

, WCG

WellCare

$287.16

0.145 (0.05%)

18:45
06/14/19
06/14
18:45
06/14/19
18:45
Hot Stocks
Centene CEO: Medicare for all will not work »

In an interview on…

CNC

Centene

$53.52

-0.26 (-0.48%)

WCG

WellCare

$287.16

0.145 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jun

  • 24

    Jun

  • 24

    Jun

  • 23

    Jul

HMC

Honda

$25.34

-0.405 (-1.57%)

18:24
06/14/19
06/14
18:24
06/14/19
18:24
Hot Stocks
Honda recalls all 2016-2019 model year Pioneer vehicles »

Honda is conducting a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$111.28

1.42 (1.29%)

18:22
06/14/19
06/14
18:22
06/14/19
18:22
Hot Stocks
RH CEO: We think our stock is massively undervalued »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DISH

Dish

$37.54

-0.35 (-0.92%)

, S

Sprint

$7.01

0.2 (2.94%)

18:08
06/14/19
06/14
18:08
06/14/19
18:08
Periodicals
Dish leads bidding for Sprint, T-Mobile assets, WSJ reports »

Dish Network (DISH) is…

DISH

Dish

$37.54

-0.35 (-0.92%)

S

Sprint

$7.01

0.2 (2.94%)

TMUS

T-Mobile

$74.90

0.44 (0.59%)

CHTR

Charter

$392.20

2.76 (0.71%)

ATUS

Altice USA

$23.82

0.15 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAL

American Airlines

$32.69

-0.39 (-1.18%)

17:31
06/14/19
06/14
17:31
06/14/19
17:31
Periodicals
American Air asks court to end 'devastating' work slowdown, Bloomberg says »

American Airlines urged a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROLL

RBC Bearings

$150.43

-3.38 (-2.20%)

17:16
06/14/19
06/14
17:16
06/14/19
17:16
Hot Stocks
RBC Bearings CEO sells over 5,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTNW

FTE Networks

$1.25

(0.00%)

17:14
06/14/19
06/14
17:14
06/14/19
17:14
Hot Stocks
FTE Networks granted financial viability exception by NYSE regulation »

FTE Networks announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$347.19

-1.54 (-0.44%)

17:14
06/14/19
06/14
17:14
06/14/19
17:14
Hot Stocks
Boeing awarded Air Force contract modification, increases ceiling by $6.53B »

Boeing has been awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 09

    Jul

MDR

McDermott

$7.60

-0.12 (-1.55%)

17:11
06/14/19
06/14
17:11
06/14/19
17:11
Hot Stocks
Chatterjee Fund Management reports 5.6% passive stake in McDermott »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PZZA

Papa John's

$50.74

0.28 (0.55%)

17:09
06/14/19
06/14
17:09
06/14/19
17:09
Hot Stocks
Papa John's dismisses KPMG as auditors, hires Ernst & Young »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 20

    Jun

  • 20

    Jun

  • 13

    Nov

EPZM

Epizyme

$11.62

-0.36 (-3.01%)

16:55
06/14/19
06/14
16:55
06/14/19
16:55
Conference/Events
Epizyme to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

CACI

CACI

$202.80

-1.205 (-0.59%)

16:54
06/14/19
06/14
16:54
06/14/19
16:54
Conference/Events
CACI to hold a conference call »

Management holds a fiscal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

HCR

Hi-Crush Inc.

$2.84

0.115 (4.22%)

16:53
06/14/19
06/14
16:53
06/14/19
16:53
Syndicate
Hi-Crush Inc files $1B mixed securities shelf »

The company also files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.